|
DE102012214540A1
|
|
Tooth filling materials and coatings for inhibiting the biofilm formation of Streptococcus mutans and their production
|
|
EP2660316A1
|
|
Avian cell line and its use in production of protein
|
|
WO2012097860A1
|
|
Novel ubiquitin-isopeptide probes
|
|
EP2581080A1
|
|
Inhibitor of colonisation of mucosa
|
|
EP2562249A1
|
|
Engineered host cells and methods for the production of cis, cis-muconic acid
|
|
EP2543372A1
|
|
Medicament for the treatment of liver cancer
|
|
EP2508607A1
|
|
Medicament for liver regeneration and for treatment of liver failure
|
|
WO2011138050A1
|
|
Method for vaccination
|
|
EP2520292A1
|
|
Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders
|
|
EP2489669A1
|
|
Haprolid and derivatives thereof as inhibitors of HCV
|
|
EP2489427A1
|
|
Device and method for production and analysis of prions
|
|
EP2487183A1
|
|
Ubiquitin-isopeptide probes
|
|
EP2476755A1
|
|
S/MAR containing expression vectors, cell and cell lines as well as methods using the same
|
|
WO2011012720A2
|
|
Compositions for generating an antigen specific immune response
|
|
EP2338521A1
|
|
Lipopeptide- and lipoprotein-conjugates and its use
|
|
EP2305283A1
|
|
Pharmaceutical compositions for treating dysregulated inflammatory diseases
|
|
EP2261325A1
|
|
Process for cell cultivation and cryopreservation
|
|
EP2258844A1
|
|
Tumour-specific bacterial promoter elements
|
|
EP2253700A1
|
|
A method for producing test systems from donors suffering from adverse effects of medicaments and /or medical treatments, and uses of said systems
|
|
EP2230312A1
|
|
Probe compound for detecting and isolating enzymes and means and methods using the same
|
